Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report
The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used as second-line therapy for advanced HCC after sora...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Liver Cancer Association
2021-09-01
|
| Series: | Journal of Liver Cancer |
| Subjects: | |
| Online Access: | http://e-jlc.org/upload/pdf/jlc-2021-08-26.pdf |
| _version_ | 1818356273335238656 |
|---|---|
| author | Ji Eun Han Hyo Jung Cho Soon Sun Kim Jae Youn Cheong |
| author_facet | Ji Eun Han Hyo Jung Cho Soon Sun Kim Jae Youn Cheong |
| author_sort | Ji Eun Han |
| collection | DOAJ |
| description | The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used as second-line therapy for advanced HCC after sorafenib failure or patient intolerance. In this case, a patient with infiltrative HCC and portal vein tumor thrombosis was treated with hepatic arterial infusion chemotherapy (HAIC) and radiation therapy. New lung metastasis developed after HAICs; thus, lenvatinib treatment was initiated. However, the disease progressed. Thereafter, sorafenib treatment was initiated but he developed intolerance, with grade 3 sorafenib-related diarrhea. Subsequently, nivolumab was administered as rescue therapy. He demonstrated a partial response to nivolumab after the third treatment and viable HCCs in the lungs and liver completely disappeared after the 24th treatment. These findings suggest that nivolumab could be used as an effective rescue therapy for advanced HCC progression after TKI treatment. |
| first_indexed | 2024-12-13T19:54:35Z |
| format | Article |
| id | doaj.art-01d6c6011f654cf8ac859d6da2595b3f |
| institution | Directory Open Access Journal |
| issn | 2288-8128 2383-5001 |
| language | English |
| last_indexed | 2024-12-13T19:54:35Z |
| publishDate | 2021-09-01 |
| publisher | Korean Liver Cancer Association |
| record_format | Article |
| series | Journal of Liver Cancer |
| spelling | doaj.art-01d6c6011f654cf8ac859d6da2595b3f2022-12-21T23:33:20ZengKorean Liver Cancer AssociationJournal of Liver Cancer2288-81282383-50012021-09-0121216917610.17998/jlc.2021.08.26481Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case reportJi Eun HanHyo Jung ChoSoon Sun KimJae Youn CheongThe current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used as second-line therapy for advanced HCC after sorafenib failure or patient intolerance. In this case, a patient with infiltrative HCC and portal vein tumor thrombosis was treated with hepatic arterial infusion chemotherapy (HAIC) and radiation therapy. New lung metastasis developed after HAICs; thus, lenvatinib treatment was initiated. However, the disease progressed. Thereafter, sorafenib treatment was initiated but he developed intolerance, with grade 3 sorafenib-related diarrhea. Subsequently, nivolumab was administered as rescue therapy. He demonstrated a partial response to nivolumab after the third treatment and viable HCCs in the lungs and liver completely disappeared after the 24th treatment. These findings suggest that nivolumab could be used as an effective rescue therapy for advanced HCC progression after TKI treatment.http://e-jlc.org/upload/pdf/jlc-2021-08-26.pdfnivolumabimmune checkpoint inhibitoradvanced hepatocellular carcinomacase report |
| spellingShingle | Ji Eun Han Hyo Jung Cho Soon Sun Kim Jae Youn Cheong Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report Journal of Liver Cancer nivolumab immune checkpoint inhibitor advanced hepatocellular carcinoma case report |
| title | Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report |
| title_full | Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report |
| title_fullStr | Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report |
| title_full_unstemmed | Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report |
| title_short | Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report |
| title_sort | infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab a case report |
| topic | nivolumab immune checkpoint inhibitor advanced hepatocellular carcinoma case report |
| url | http://e-jlc.org/upload/pdf/jlc-2021-08-26.pdf |
| work_keys_str_mv | AT jieunhan infiltrativehepatocellularcarcinomawithmultiplelungmetastasiscompletelycuredusingnivolumabacasereport AT hyojungcho infiltrativehepatocellularcarcinomawithmultiplelungmetastasiscompletelycuredusingnivolumabacasereport AT soonsunkim infiltrativehepatocellularcarcinomawithmultiplelungmetastasiscompletelycuredusingnivolumabacasereport AT jaeyouncheong infiltrativehepatocellularcarcinomawithmultiplelungmetastasiscompletelycuredusingnivolumabacasereport |